Treatment protocols Diseases Stroke CP ALS SCI PD Autism Dementia MS Total number of treated patients 23 38 19 19 15 16 18 52 Subcutaneous medications Filgrastim 15μg/Kg/d 15 26 16 15 10 11 11 26 Erythropoietin 100 U/Kg/d 13 - - - - - - - Intravenous medications Cerebrolysin Before ASCT 1ml/5kg/6h 7 23 7 5 5 4 12 28 After ASCT 20 30 13 7 11 7 16 40 Citicoline Before ASCT 10mg/kg/6h 14 17 5 - 8 5 7 22 After ASCT 18 28 10 5 10 10 16 35 Per os medications Citicoline Solution 1ml/10kg/d 16 25 6 8 7 10 13 30 Cytidine 5'Monophosphate Uridine Triphosphate 1mg/6Kg/d 1mg/10Kg 16 12 12 8 6 7 12 26 Adenosine Triphosphate 1mg/Kg/d 14 8 7 6 9 5 10 15 Omega 3 20mg/ Kg/d 16 19 10 4 6 7 15 37 Vimpocetine Huperzine A Lecithin 10mg/d 100 mcg/d 100 mg/d 16 27 12 12 7 10 13 33 Atorvastatin 20 mg/d 8 - - - - - - - Technical Bone marrow needle 1.5 mm 11 20 6 11 9 9 7 25 2.0 mm 12 18 13 8 6 7 11 27 Biopsy site (iliac crest) Unilateral posterior superior 2 10 3 3 3 4 2 10 Posterior Superior 18 20 14 5 10 10 12 29 Posterior Superior + Anterior 3 8 2 11 2 2 4 13 Incubation Period short 17 22 14 10 9 8 11 35 medium 4 12 4 7 4 5 5 11 long 2 4 1 2 2 3 3 6 Temperature 4-8 °C 3 8 2 4 4 2 6 5 20-24 °C 15 24 13 10 9 10 5 33 37 °C 5 6 4 5 2 4 7 14 Agent Eco-ultrafiltrate 17 17 11 9 6 6 11 25 Shaker 10 16 7 9 5 6 8 12 Procedural Infusion route Intravenous 3 4 2 - 3 4 2 5 lumbar puncture 3 5 3 11 3 3 2 6 Intravenous + lumbar puncture 17 29 14 8 9 9 14 41 Mannitol 20% intravenous bolus 19 22 11 6 9 4 16 34 Trendelenburg position 1 h 7 9 15 - 6 5 11 24 3 h 12 16 2 - 4 7 4 19 10 h 4 13 2 - 5 4 3 9 Late and long-term measures Hyperbaric oxygen therapy ­- 12 - - - 6 -­ - Neurorehabilitation and neuroreeducation 15 33 15 17 5 8 - 46 MS – Multiple Sclerosis PD – Parkinson Disease CP – Cerebral Palsy SCI – Spinal Cord Injury ALS – Amyotrophic Lateral Sclerosis

Table 3: Variety of treatment protocols applied to all categories of patients.